NEW YORK – With the recent launch of its Hazel finger prick-based
prenatal genetic screening test, Juno Diagnostics aims to reduce barriers to access in the noninvasive prenatal testing (NIPT) market.
The tests, which screen for trisomies 13, 18, and 21, require a physician's order but blood collection can be performed at home, removing the need for phlebotomy, which is both more invasive and inconsistently available, particularly to patients in rural areas. "People think that phlebotomy is always there, and it's not," said Dirk van den Boom, Juno's founder and CEO. Previously, van den Boom spent almost 20 years at Sequenom, one of the first companies to bring
an NIPT for chromosomal abnormalities to market, becoming the firm's president and CEO in 2015 prior to its acquisition by Labcorp in 2016.